Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00969436
Other study ID # 109995
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 9, 2009
Est. completion date February 21, 2011

Study information

Verified date May 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorix™ administered at 9 months of age followed by concomitant administration of Priorix™ with Varilrix™ at 15 months of age in a measles endemic environment such as India.


Recruitment information / eligibility

Status Completed
Enrollment 450
Est. completion date February 21, 2011
Est. primary completion date February 21, 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 9 Months to 10 Months
Eligibility Inclusion Criteria:

- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.

- Male or female subjects between and including 9 and 10 months of age at the time of the first vaccination.

- Written informed consent obtained from the the parent or guardian of the subject.

- Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

- Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.

- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

- Planned administration/administration of a vaccine not foreseen by the study protocol starting 30 days prior to administration of any dose of the study vaccine, up to 42 days after the vaccine dose with the exception of hepatitis A vaccine and oral poliovirus vaccine .

- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-registered product.

- Previous vaccination against measles, mumps, rubella and varicella.

- History of measles, mumps, rubella and/or varicella diseases.

- Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to the start of the study.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

- A family history of congenital or hereditary immunodeficiency.

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines including neomycin.

- Major congenital defects or serious chronic illness.

- History of any neurologic disorders or seizures.

- Acute disease at the time of enrolment.

- Axillary temperature > 37.5°C (99.5°F) / Rectal temperature > 38°C (100.4°F).

- Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period.

- Presence of a susceptible high-risk person in the same household during the study period.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GSK Biological's investigational MMRV vaccine 208136
Subcutaneous injection
Priorix™
Subcutaneous injection
Varilrix™
Subcutaneous injection

Locations

Country Name City State
India GSK Investigational Site Bangalore
India GSK Investigational Site Chennai
India GSK Investigational Site Goa
India GSK Investigational Site Kolkata
India GSK Investigational Site Pune
India GSK Investigational Site Pune

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies Seroconversion was defined as the appearance of antibodies [i.e. concentration/titre greater than or equal to (=) the cut-off value] in the serum of subjects seronegative before vaccination. The cut-off values for seroconversion were 150 milli-international units per milliliter (mIU/mL), 231 units per milliliter (U/mL), 4 international units per milliliter (IU/mL) and for immunoglobulin G (IgG) varicella antibodies 1:4 dilution for measles, mumps, rubella and varicella, respectively. At 42 - 56 days after the second vaccination dose at week 30
Secondary Number of Seroconverted Subjects for Measles, Mumps, Rubella and Varicella Antibodies Seroconversion was defined as the appearance of antibodies (i.e. concentration/titre = the cut-off value) in the serum of subjects seronegative before vaccination. The cut-off values for seroconversion were 150 mIU/mL, 231 U/mL, 4 IU/mL and for IgG varicella antibodies 1:4 dilution for measles, mumps, rubella and varicella, respectively. Approximately 42 to 56 days after the first vaccine dose at week 6
Secondary Antibody Concentrations Against Measles, Mumps, Rubella and Varicella Viruses Antibody concentrations were summarized by geometric mean concentrations (GMCs) with their 95% confidence intervals (CIs). At 42 - 56 days after the first (at Week 6) and second (at Week 30) vaccination dose
Secondary Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site. During the 4-day (Days 0-3) post-vaccination period following each dose (Dose 1 and Dose 2)
Secondary Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Assessed solicited general symptoms were meningism and parotid gland swelling. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 meningism and parotid gland swelling = meningism/parotid gland swelling which prevented normal everyday activities. Related = symptom assessed by the investigator as related to the vaccination. During the 43-day (Days 0-42) post-vaccination period following each dose (Dose 1 and Dose 2)
Secondary Number of Subjects Reporting Any, Grade 3 and Related Fever Any fever was defined as fever = 38.0°C and grade 3 fever was defined as fever > 39.5°C after vaccination. Related fever was defined as fever assessed by the investigator as related to the vaccination. During the 43-day (Days 0-42) post-vaccination period following each dose (Dose 1 and Dose 2)
Secondary Number of Subjects Reporting Any, Grade 3 and Related Rash Any rash was defined as incidence of a rash regardless of intensity grade or relationship to vaccination and grade 3 rash greater than (>) 150 lesions. Related rash was defined as rash assessed by the investigator as causally related to the vaccination During the 43-day (Days 0-42) post-vaccination period following each dose (Dose 1 and Dose 2)
Secondary Number of Subjects Reporting Any Unsolicited Adverse Event An unsolicited Adverse Event (AE) covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Within 43-day (Days 0-42) after the first and second vaccination dose
Secondary Number of Subjects With Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or congenital anomaly/birth defect in the offspring of a study subject. From the first study dose up to study end (Month 0 to Month 7.5 approximately)
See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Phase 1
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT01681992 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4
Completed NCT03148990 - Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Phase 2/Phase 3